*Statistical significance for dyspareunia was not achieved with the 150 mg QD dose of ORILISSA.
ORILISSA was rigorously studied in 2 clinical trials and 2 extension studies with strictly defined endpoints and clinically meaningful responses.1,3,4
Two robust similar multicenter, double-
blind, randomized, prospective,
placebo-controlled phase 3 trials
of 6-month treatment at 2 doses.1,3
Explore the response rates
and endometriosis pain score
results for 2 ORILISSA doses.1
Read about adverse
reactions and safety
profile for ORILISSA.
Back to top